In this issue of Blood, Cooke et al demonstrate the potential of a fully human 
anti-hepcidin antibody as a novel therapeutic for iron-restricted anemias such 
as anemia of inflammation, cancer, or chronic kidney disease (formerly known as 
“anemia of chronic diseases”).